about
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionNonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionHost innate immune receptors and beyond: making sense of microbial infections.Innate immune response to viral infection.Innate immune control of nucleic acid-based vaccine immunogenicity.Innate and adaptive immune responses to viral infection and vaccination.Lamtor1 Is Critically Required for CD4(+) T Cell Proliferation and Regulatory T Cell Suppressive Function.Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Development of Selective Covalent Janus Kinase 3 Inhibitors.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers.Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9.Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database.Cutting Edge: TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells.Double deletion of tetraspanins CD9 and CD81 in mice leads to a syndrome resembling accelerated aging.Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EB.Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization.Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in miceMycobacterial hypersensitivity pneumonitis requires TLR9-MyD88 in lung CD11b+ CD11c+ cellsTANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccinesSelecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironmentThe role of multiple toll-like receptor signalling cascades on interactions between biomedical polymers and dendritic cellsApoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosusMonitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysisSequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumorsAuthor Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumorsSuccessful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions
P50
Q27853339-F4D257C8-678B-45CB-BB66-AC34CFEA32C2Q28383385-173A45CD-B89E-435E-B7A1-0E60A8317E9CQ30573156-8FF6AB5F-C7B9-4472-9BA1-2FD98B2D4EC3Q33956097-F9B25420-FB51-4B88-A2F3-F576F3E94569Q34785533-F6B269C4-110E-4901-9E7C-31570CC7ADEFQ37241258-CCB16DC4-D99E-4DF2-AB78-F9875F0401C4Q37559651-563E5A26-EC32-4307-A227-1A881521843FQ37996191-79B4D6EB-5118-4565-BE19-E69D154336F4Q38646068-97DE889E-579E-45AF-BD96-704941376B10Q38707220-3445831F-5F35-4750-A0C4-1151F4DCA27FQ38731119-105FBA5D-D56F-4BD2-9F3C-EA2CBE183A20Q38763094-B88D6CD2-DB7E-4B59-91CC-1E8357EBBE08Q38797202-DBB49CAE-66D3-4CC3-B7E6-D75E0F1724A5Q39089944-859BB778-191C-41E8-9D13-CBFA111A3CD7Q41819380-A6DD6785-EC9D-4C5D-A027-2F1FB95E3229Q42564555-405A11A0-AF8D-4DF0-8E54-98194D91DE75Q44429644-D9A569FC-C81D-494F-97A0-BD65D169C413Q45184856-D2B3FA9C-9062-4989-B6E6-5C7D186B9E67Q47660305-8C1EB32C-7504-459A-BD1B-D93926F5CD9DQ47790283-1520D9FA-886B-4F60-A81D-7C272D795D64Q47886161-13A97CDD-F47A-4C07-80CB-713EB24E189FQ47926367-2B6910C3-5D1A-4F07-9AE1-988FECB40F56Q51322059-E66FF765-9C01-442B-B690-B45898112DFFQ51434967-08FC57BB-9237-4F98-A5B8-F7824F7E8340Q51758901-FC9D54C8-1C9A-46A2-AB39-34F1163CAA96Q51760032-9178A7B3-6A95-4166-8AE2-83B21058941BQ52312134-0EB92BA9-780D-40CA-850E-CDE3905DB5CCQ54108748-6D4DDC71-547D-4B1A-BE91-0B56458D0B87Q56897607-D928767D-AA66-4535-8E15-ED672D0461C9Q56897615-8AE8415B-69AC-41B7-BBB9-360AA870AFEAQ56897738-9DCD2903-54F5-4619-B17F-FA158159B509Q58704671-39D03CA4-FAB7-4D42-9621-B7C9917D7A16Q61583821-0ADF9E88-1929-4638-B726-2D0DD9946A56Q89266529-078D8E96-AE91-43FC-B3A3-84E815CEFDF3Q90104113-1CE35B9F-A10E-461B-98BF-CBD69B944656Q90929525-C3241AA8-7511-4340-B906-218DDF5782A0Q91168933-53F48463-2F72-4884-88A0-FFF71EF80505Q96610741-F5BDE424-7F67-4E48-AEA6-7D41309C669F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shohei Koyama
@ast
Shohei Koyama
@en
Shohei Koyama
@es
Shohei Koyama
@nl
Shohei Koyama
@sl
type
label
Shohei Koyama
@ast
Shohei Koyama
@en
Shohei Koyama
@es
Shohei Koyama
@nl
Shohei Koyama
@sl
prefLabel
Shohei Koyama
@ast
Shohei Koyama
@en
Shohei Koyama
@es
Shohei Koyama
@nl
Shohei Koyama
@sl
P106
P108
P1153
55701302900
P31
P496
0000-0002-6897-9417